SSY Group (HK:2005) has released an update.
SSY Group Limited has announced that two of its pharmaceutical products, Alogliptin Benzoate for treating type 2 diabetes and Betahistine Hydrochloride for vertigo and related symptoms, have received registration approvals from China’s National Medical Products Administration. This marks a significant step for the company in bringing these bulk drugs to the market, reflecting their ongoing commitment to medical innovation and shareholder communication.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.
